# Eric Van Cutsem
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/eric-van-cutsem/
## Facts
| Field | Value |
| --- | --- |
| Citations | 177,504 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 177 |
| i10-index | 850 |
| Last Known Institution | Universitair Ziekenhuis Leuven |
| OpenAlex ID | https://openalex.org/A5090645179 |
| ORCID iD | https://orcid.org/0000-0002-6372-1230 |
| Works | 1,840 |
## Researcher papers
Showing 12 of 26.
- [Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/sunitinib-malate-for-the-treatment-of-pancreatic-neuroendocrine-tumors/)
- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer](https://scholariq.org/papers/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/)
- [Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-for-the-treatment-of-advanced-non-functional-neuroendocrine-tumours/)
- [Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-plus-octreotide-long-acting-repeatable-for-the-treatment-of-advanced/)
- [Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study](https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/)
- [KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab](https://scholariq.org/papers/kras-wild-type-state-predicts-survival-and-is-associated-to-early-radiological/)
## Researcher topics
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
## Researcher university
- [Universitair Ziekenhuis Leuven](https://scholariq.org/institutions/universitair-ziekenhuis-leuven/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.